Determination of maximum tolerated dose and ED95 of intranasal dexmedetomidine and sufentanil in endoscopic ultrasonography

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019273

Enrollment

Unknown

Registered

2018-11-02

Start date

2018-11-02

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive disease

Interventions

Case series:intranasal administration of dexmedetoidine/sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing endoscopic ultrasonography; Aged 18 to 65 year; ASA I-III.

Exclusion criteria

Exclusion criteria: 1. Presence of otorhinolaryngeal diseases (e.g., status post-surgery, rhinitis, nasal polyposis); 2. Severe cardiac conduction block (HR 28 kg/m2; 5. Mallampati grading = 3 grade; 6. general contraindications for the use of dexmedetomidine or sufentanil (i.e., allergic reactions etc.); 7. preexisting hypoxia (oxygen saturation < 88%); 8. respiratory rate <10/min; 9. achalasia.

Design outcomes

Primary

Measure	Time frame
respiratory depression;The Observer's Assessment of Alertness/Sedation Scale;	—

Secondary

Measure	Time frame
adverse events;vital signs;satisfaction rating;gag reflex;Modified Aldrelet score;	—

Countries

China

Contacts

Public ContactYi Zou

Beijing Friendship Hospital, Capital Medical University

zouyi871123@126.com+86 10-63138780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026